Buyout includes $51.9 million payout to Synthes' top executive

12/5/2011 | MassDevice.com (Boston)

Michel Orsinger, CEO of Synthes, will receive a $51.9 million payout as part of a $21.3 billion acquisition by Johnson & Johnson. The buyout, which is expected to be completed early next year, will allow Johnson & Johnson to add Synthes to its DePuy unit, with Orsinger taking over as head of the company's new global orthopedics team.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC
Healthcare Compliance Manager
Ernst & Young
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC